期刊文献+

拉米夫定联合干扰素α-1b治疗慢性乙型病毒性肝炎35例 被引量:1

下载PDF
导出
摘要 目的探讨拉米夫定联合干扰素α-1b(IFNα-1b)治疗慢性乙型病毒性肝炎(CHB)的临床疗效。方法将97例患者分成3组,拉米夫定组疗程12个月,干扰素组6个月,联合治疗组为拉米夫定(1年)联合IFNα-1b(6个月)。结果联合治疗组HBV-DNA阴转率高于干扰素组(P<0.01),HBeAg阴转率和抗-HBe阳转率均高于拉米夫定组(P<0.01),血清转氨酶复常率优于拉米夫定组和干扰素组(P<0.01)。结论拉米夫定联合IFNα-1b治疗CHB的疗效优于单一用药。
出处 《中国药业》 CAS 2006年第4期56-57,共2页 China Pharmaceuticals
  • 相关文献

参考文献3

二级参考文献28

  • 1Feld J, Lee JY, Locarnini S. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology,2003, 38: 545-553.
  • 2Perelson AS, Ribeiro RM. Hepatitis B virus linetics and mathematical modeling. Semin Liver Dis, 2004, 24(Suppl 1): 11-16.
  • 3Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol, 2003, 77: 68-76.
  • 4Perrillo RP. Overview of treatment of hepatitis B: key approaches and clinical challenges. Semin Liver Dis, 2004, 24(Suppl 1): 23-29.
  • 5Wright TL. Clinical trial results and treatment resistance with Lamivudine for hepatitis B. Semin Liver Dis, 2004, 24(Suppl 1): 31-36.
  • 6Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis, 2004, 24(Suppl 1): 3-10.
  • 7Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology,2003, 125: 1714-1722.
  • 8Liaw YF, Chien RN, Yeh CT. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther, 2004,
  • 9: 257-262.9.Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med, 2003, 348: 808-816.
  • 10Westland CE, Yang H, Delaney WE, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology, 2003, 38: 96-103.

共引文献14062

同被引文献7

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部